Ortec International, Inc., a tissue-engineering company, announced that it will use a dedicated sales force provided by PDI, a pharmaceutical and medical device and diagnostics sales and marketing company, to target the donor site burn market. OrCel™, a biologically active wound agent, will be launched during the first quarter of 2002 throughout the United States. OrCel is the only product containing living human cells approved by the FDA for healing donor site wounds in burn patients.
Ortec International, Inc., is a tissue-engineering company involved in the commercialization of a proprietary and patented technology to stimulate the repair and regeneration of human tissue. Ortec’s current focus is the application of OrCel to heal chronic and acute wounds. In addition to having received FDA approvals this year for OrCel for treatment of epidermolysis bullosa and donor sites in burn patients, Ortec is also pursuing FDA approvals for venous and diabetic skin ulcers and is in the midst of clinical trials for these indications. Ortec believes that its platform technology extends to the regeneration of other human tissue, such as tendons, ligaments, cartilage, bone, muscle, and blood vessels. For more information, visit www.ortecinternational.com.